Abstract
SARS-CoV-2 remains an acute threat to human health, endangering hospital capacities worldwide. Many studies have aimed at informing pathophysiologic understanding and identification of disease indicators for risk assessment, monitoring, and therapeutic guidance. While findings start to emerge in the general population, observations in high-risk patients with complex pre-existing conditions are limited.
To this end, we biomedically characterized quantitative proteomics in a hospitalized cohort of COVID-19 patients with mild to severe symptoms suffering from different (co)-morbidities in comparison to both healthy individuals and patients with non-COVID related inflammation. Deep clinical phenotyping enabled the identification of individual disease trajectories in COVID-19 patients. By the use of this specific disease phase assignment, proteome analysis revealed a severity dependent general type-2 centered host response side-by-side with a disease specific antiviral immune reaction in early disease. The identification of phenomena such as neutrophil extracellular trap (NET) formation and a pro-coagulatory response together with the regulation of proteins related to SARS-CoV-2-specific symptoms by unbiased proteome screening both confirms results from targeted approaches and provides novel information for biomarker and therapy development.
Graphical Abstract Sars-CoV-2 remains a challenging threat to our health care system with many pathophysiological mechanisms not fully understood, especially in high-risk patients. Therefore, we characterized a cohort of hospitalized COVID-19 patients with multiple comorbidities by quantitative plasma proteomics and deep clinical phenotyping. The individual patient’s disease progression was determined and the subsequently assigned proteome profiles compared with a healthy and a chronically inflamed control cohort. The identified disease phase and severity specific protein profiles revealed an antiviral immune response together with coagulation activation indicating the formation of NETosis side-by-side with tissue remodeling related to the inflammatory signature.
Competing Interest Statement
The authors declare no conflict of interest apart from Clemens Scherer, who received speaker honoraria from AstraZeneca, outside the submitted work. All authors were involved in the decision to publish and reviewed the article before submission.
Funding Statement
This study was supported by COMBAT C19IR (01KI20249), funded by the Federal Ministry of Education and Research (BMBF) and the Free State of Bavaria under the Excellence Strategy of the Federal and State Government (LMUexcellent), as well as partially funded by the Bavarian Ministry for Economic Affairs, Regional Development and Energy as part of a project to support the thematic development of the Institute for Cognitive Systems (IKS). The present study was supported by the German Center for Lung Research (DZL, German Ministry of Education and Health (BMBF)) as well as the Research Training Group Targets in Toxicology (GRK2338) of the German Science and Research Organization (DFG). Additional financial support was provided by the Stiftung AtemWeg (LSS AIRR) and by the Helmholtz Association`s Initiative and Networking Fund through Helmholtz AI.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients and control subjects are part of the COVID-19 Registry of the LMU University Hospital Munich (CORKUM, WHO trial id DRKS00021225). Patient data were anonymized for analysis. The study was approved by the ethics committee of the Ludwig-Maximilians-Universitaet (LMU), Munich, Germany (Study title: "COVID-19 Register des LMU Klinikums (CORKUM)"; Project No: 20-245 (initial approval date: 03/2020; Amendment approval dates: 07/2020, 01/2021, 05/2021) as well as under the Project No: 20-259 (CPC-M bioArchive)).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding authors upon request. Access to data for research purposes is possible for eligible institutes according to GDPR rules.
